Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.

Autor:	Heigener DF; Lungenclinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.; Chrisitan-Albrechts-University, Kiel, Germany., Reck M; Lungenclinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.; Luebeck University, Luebeck, Germany.
Jazyk:	angličtina
Zdroj:	Journal of thoracic disease [J Thorac Dis] 2018 May; Vol. 10 (Suppl 13), pp. S1468-S1473.
DOI:	10.21037/jtd.2018.01.112
Abstrakt:	PD-L1 and PD-1 inhibitors were both developed to combat a huge array of cancers. Both classes of agents block the PD-1/PD-L1 pathway. Unlike PD-1 inhibitors, PD-L1 inhibitors do also block the B-7.1-receptor and leave the PD-L2/PD-1 axis unaffected. Whether these differences enhance efficacy and tolerability is not clear yet. There are three PD-L1 inhibitors approved or in late clinical development: Atezolizumab, approved in 2 nd -line treatment of non-small cell lung cancer, durvalumab, showing promising results as a consolidation therapy in stage III disease and avelumab, the only drug exploiting antigen-dependent cytotoxicity. Future directions are the combination of these compounds with chemotherapy or other immuno-oncologic drugs. Competing Interests: Conflicts of Interest: DF Heigener: Advisory Board: Boehringer Ingelheim, Roche, BMS, MSD, Pfizer, Lilly, Astra Zeneca, Chugai, Fresenius; Honoraria for Speeches: Boehringer Ingelheim, Roche, BMS, MSD, Pfizer, Lilly, Astra Zeneca; Travel Reimbursement: Boehringer Ingelheim, Roche, BMS, MSD, Pfizer, Lilly, AstraZeneca, Chugai, Fresenius. M Reck: Advisory Board: Boehringer Ingelheim, Roche, BMS, MSD, Pfizer, Lilly, Astra Zeneca, Chugai; Honoraria for Speeches: Boehringer Ingelheim, Roche, BMS, MSD, Pfizer, Lilly, AstraZeneca; Travel Reimbursement: Boehringer Ingelheim, Roche, BMS, MSD, Pfizer, Lilly, Astra Zeneca, Chugai, Fresenius.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu